



US009409972B2

(12) **United States Patent**  
**Uto et al.**

(10) **Patent No.:** **US 9,409,972 B2**  
(45) **Date of Patent:** **\*Aug. 9, 2016**

(54) **PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING SAME**

- (71) Applicants: **SAISEI MIRAI CLINIC**, Moriguchi-shi, Osaka (JP); **TOKUSHIMA UNIVERSITY**, Tokushima-shi, Tokushima (JP)
- (72) Inventors: **Yoshihiro Uto**, Tokushima (JP); **Hitoshi Hori**, Tokushima (JP); **Toshio Inui**, Moriguchi (JP); **Kentaro Kubo**, Moriguchi (JP)
- (73) Assignees: **TOKUSHIMA UNIVERSITY**, Tokushima-Shi (JP); **SAISEI MIRAI CLINIC**, Moriguchi-Shi (JP)
- (\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.  
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/193,362**

(22) Filed: **Feb. 28, 2014**

(65) **Prior Publication Data**

US 2014/0213522 A1 Jul. 31, 2014

**Related U.S. Application Data**

(63) Continuation of application No. 13/988,376, filed as application No. PCT/JP2012/072884 on Sep. 7, 2012, now Pat. No. 8,747,919.

(30) **Foreign Application Priority Data**

Sep. 14, 2011 (JP) ..... 2011-200684

- (51) **Int. Cl.**  
*A01N 65/00* (2009.01)  
*C07K 14/765* (2006.01)  
*A61K 35/16* (2015.01)  
*A61K 38/47* (2006.01)

(52) **U.S. Cl.**  
CPC ..... *C07K 14/765* (2013.01); *A61K 35/16* (2013.01); *A61K 38/47* (2013.01)

(58) **Field of Classification Search**  
CPC ..... A61K 36/00  
USPC ..... 424/725  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

2004/0224877 A1 11/2004 Pirie-Shepherd et al.

**FOREIGN PATENT DOCUMENTS**

EP	2612921 A1	7/2013
JP	5-97695 A	4/1993
JP	6-99314 B2	12/1994
WO	WO 2012/029954 A1	3/2012

**OTHER PUBLICATIONS**

- Oberstein et al., *Therap Adv Gastroenterol.* Jul. 2013; 6(4): 321-337.\*
- International Preliminary Report on Patentability with Written Opinion, dated Mar. 16, 2014, for Application No. PCT/JP2012/072884 with English language translation.
- Hori et al., "Drug discovery of dramatype-anticancer drugs base on oligosaccharide-processing of Gc protein (vitamin D-binding protein)," *Radiation Biology Research Communications*, vol. 39, No. 3, Sep. 29, 2004, pp. 328-341.
- International Search Report issued in PCT/JP2012/072884, mailed on Oct. 23, 2012.
- Uto et al., "B-Galactosidase Treatment is a Common First-stage Modification of the Three Major Subtypes of Gc Protein to GcMAF", *Anticancer Research*, vol. 32, 2012, pp. 2359-2364.
- Uto et al., "Effect of the Gc-derived Macrophase-activating Factor Precursor (preGcMAF) on Phagocytic Activation of Mouse Peritoneal Macrophages", *Anticancer Research*, vol. 31, 2011, pp. 2489-2492.
- Yamamoto et al., "Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GmMAF1", *Translational Oncology*, vol. 1, No. 2, Jul. 2008, pp. 65-72.
- Yamamoto et al., "Immunotherapy of HIV-Infected Patients With Gc Protein-Derived Macrophage Activating Factor (GcMAF)," *Journal of Medical Virology*, vol. 81, No. 1, 2009, pp. 16-26.
- Yamamoto et al., "Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)", *Int. J. Cancer*, vol. 122, 2008, pp. 461-467.
- Yamamoto et al., "Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF", *Cancer Immunol Immunother*, vol. 57, 2008, pp. 1007-1016.
- Yamamoto et al., "Role of Vitamin D3-Binding Protein in Activation of Mouse Macrophages," *The Journal of Immunology*, vol. 157, No. 4, Aug. 15, 1996, pp. 1744-1749.
- Yamamoto et al., "Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes," *Proceedings of the Nat'l Academy of Sciences of the United States of America*, vol. 88, No. 19, Oct. 1991, pp. 8539-8543.
- Extended European Search Report dated Dec. 10, 2014 for European Application No. 12831559.5.

\* cited by examiner

*Primary Examiner* — Michael Meller

(74) *Attorney, Agent, or Firm* — Birch, Stewart, Kolasch & Birch, LLP

(57) **ABSTRACT**

An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with β-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.